AlphaCore Capital’s Fate Therapeutics FATE Stock Holding History

AlphaCore Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,689	Closed	-$12.5K	–	1328
2025 Q4	$12.5K	Buy	+12,689	New	+$15.2K	﹤0.01%	1302

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCore Capital's FATE Position: Q1 2026 in Review

AlphaCore Capital sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 12,689 shares — an estimated $12.5K sold.

AlphaCore Capital first reported a position in FATE in Q4 2025 and held it in 1 quarter. The position peaked at $12.5K in Q4 2025. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

AlphaCore Capital reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaCore Capital sold 12,689 Fate Therapeutics shares in Q1 2026, an estimated $12.5K.
AlphaCore Capital first reported a position in Fate Therapeutics in Q4 2025 and held it in 1 quarter.
AlphaCore Capital's Fate Therapeutics position peaked at $12.5K in Q4 2025.
157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.